Vasoflux, a new anticoagulant with a novel mechanism of action

Circulation

Volumn 99, Issue 5, 1999, Pages 682-689

  Weitz, Jeffrey ^a   Young, Edward ^b   Johnston, Marilyn ^b   Stafford, Alan R ^b   Fredenburgh, James C ^b   Hirsh, Jack ^b  

^a HAMILTON HEALTH SCIENCES   (Canada)

^b NONE

Author keywords

Anticoagulants; Coagulation; Heparin

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR; ENOXAPARIN; FIBRIN; HEPARIN; HEPARIN DERIVATIVE; HIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PERIODATE; STREPTOKINASE; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; VASOFLUX;

ACUTE HEART FAILURE; ARTICLE; BLOOD CLOT LYSIS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SYNTHESIS; FIBRINOLYTIC THERAPY; MOLECULAR SIZE; PRIORITY JOURNAL;

EID: 0033537508     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.99.5.682     Document Type: Article

References (32)

1. Theroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med. 1992; 327:141-145.
2. Granger CB, Miller JM, Bovill E, Gruber A, Tracy RP, Krucoff MW, Green C, Berrios E, Harrington RA, Ohman EM, Califf R. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation. 1995;91: 1929-1935.
3. Merlini PA, Bauer K, Oltrona L, Ardissino D, Spinola A, Cattaneo M, Broccolino M, Mannucci PM, Rosenberg RD. Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction. J Am Coll Cardiol. 1995;25:203-209.
4. Granger CB, Becker R, Tracy RP, Califf RM, Topol EJ, Pieper KS, Ross AM, Roth SR, Lambrew C, Bovill EG, for the GUSTO Hemostasis Substudy Group. Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: results from the GUSTO trial. J Am Coll Cardiol. 1998;31:497-505.
5. Teitel JM, Rosenberg RD. Protection of factor Xa from neutralization by the heparin-antithrombin complex. J Clin Invest. 1983;71:1383-1391.
6. Eisenberg PR, Siegel JE, Abendschein DR, Miletich JP. Importance of factor Xa in determining the procoagulant activity of whole-blood clots. J Clin Invest. 1993;91:1877-1888.
7. Hogg PJ, Jackson CM. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy. Proc Natl Acad Sci U S A. 1989;86:3619-3623.
8. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990;86:385-391.
9. Kumar R, Beguin S, Hemker C. The effect of fibrin clots and clot-bound thrombin on the development of platelet procoagulant activity. Thromb Haemost. 1995;74:962-968.
10. Kumar R, Beguin S, Hemker C. The influence of fibrinogen and fibrin on thrombin generation: evidence for feedback activation of the clotting system by clot-bound thrombin. Thromb Haemost. 1994;72:713-721.
11. Rao AK, Sun L, Chesebro JH, Fuster V, Harrington RA, Schwartz D, Gallo P, Matos D, Topol EJ, for the Hirudin in Unstable Angina Trial. Distinct effects of recombinant desulfatohirudin (Revasc) and heparin on plasma levels of fibrinopeptide A and prothrombin fragment F1.2 in unstable angina: a multicenter trial. Circulation. 1996;94:2389-2395.
12. Gold HK, Torres FW, Garabedian HD, Werner W, Jang I, Khan I, Hagstrom JN, Yasuda T, Leinbach RC, Newell JB, Bovill EG, Stump DC, Collen D. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. J Am Coll Cardiol. 1993;21:1039-1047.
13. The Gusto IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med. 1996;335:775-782.
14. Serruys PW, Herrman JR, Simon R, Rutsch W, Bode C, Laarman G-J, van Dijk R, van den Bos AA, Umans VAWM, Fox KAA, Close P, Deckers JW, for the Helvetica Investigators. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med. 1995;333:757-763.
15. Tollefsen DM, Pestka CA, Monato WJ. Activation of heparin cofactor II by dermatan sulphate. J Biol Chem. 1983;258:6713-6716.
16. Bendayan P, Boccalon H, Dupouy D, Boneu B. Dermatan sulfate is a more potent inhibitor of clot-bound thrombin than unfractionated and low molecular weight heparin. Thromb Haemost. 1994;71:576-580.
17. Okwusidi J, Anvari K, Kulczycky M, Blajchman MA, Buchanan MR, Ofosu FA. Fibrin moderates the catalytic action of heparin but not that of dermatan sulfate on thrombin inhibition in human plasma. J Lab Clin Med. 1991;117:359-364.
18. Cosmi B, Fredenburgh JC, Rischke J, Hirsh J, Young E, Weitz JI. Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate. Circulation. 1997;95:118-124.
19. Cosmi B, Agnelli G, Young E, Hirsh J, Weitz J. The additive effect of low molecular weight heparins on thrombin inhibition by dermatan sulfate. Thromb Haemost. 1993;70:443-447.
20. Olson ST, Bjork I, Shore JD. Kinetic characterization of heparin catalysed and uncatalysed inhibition of blood coagulation proteinases by antithrombin. Methods Enzymol. 1993;222:525-559.
21. Bloom JW, Nesheim ME, Mann KG. Phospholipid-binding properties of bovine factor V and factor Va. Biochemistry: 1979;18:4419-4425.
22. Young E, Cosmi B, Weitz J, Hirsh J. Comparison of the non-specific binding of unfractionated heparin and low molecular weight heparin (Enoxaparin) to plasma proteins. Thromb Haemost. 1993;70:625-630.
23. Nesheim M, Fredenburgh JC, Larsen GR. The dissociation constants and stoichiometries of the interactions of lys-plasminogen and chloromethyl ketone derivatives of tissue plasminogen activator and the variant ΔFEIX with intact fibrin. J Biol Chem. 1990;265:21541-21548.
24. Fredenburgh J, Stafford AR, Weitz JI. Evidence for allosteric linkage between exosites 1 and 2 of thrombin. J Biol Chem. 1997;272: 25493-25499.
25. Winer BJ. Statistical Principles in Experimental Design. 2nd ed. New York, NY: McGraw-Hill; 1962:549-599.
26. Weitz JI, Young E, Klement P, Hirsh J. Vasoflux, a novel anticoagulant that is more effective than heparin and safer than hirudin in rabbits. Blood. 1997;90:298. Abstract.
27. Zoldhelyi P, Webster MWI, Fuster V, Grill DE, Caspar D, Edwards SJ, Cabot CF, Chesebro JH. Recombinant hirudin in patients with chronic, stable coronary artery disease: safety, half-life, and effect on coagulation parameters. Circulation. 1993;88:2015-2022.
28. Agnelli G, Cosmi B, DiFilippo P, Ranucci V, Veschi F, Longetti M, Renga C, Barzi F, Gianese F, Lupattelli L, Rinonapoli E, Nenci GG. A randomised, double-blind, placebo-controlled trial of dermatan sulphate for prevention of deep vein thrombosis in hip fracture. Thromb Haemost. 1992;67:203-208.
29. Hirsh J. Heparin. N Engl J Med. 1991;324:1565-1574.
30. Weitz JI. Low-molecular-weight heparins. N Engl J Med. 1997;337: 688-698.
31. Jordan RE, Oosta GM, Gardner WT, Rosenberg RD. The binding of low molecular weight heparin to hemostatic enzymes. J Biol Chem. 1980; 255:10073-10080.
32. Barrow RT, Parker ET, Krishnaswamy S, Lollar P. Inhibition by heparin of the human blood coagulation intrinsic pathway factor X activator. J Biol Chem. 1994;269:26796-26800.